by Kyle | Jul 25, 2022 | News
The Rapid Quantitative Tear Test for MMP-9 from AXIM Biotechnologies Inc. was featured in a list of DED Diagnostic tools in Optometric Management.com. See the list below: DED Diagnostic Items* BLINK ASSESSMENT iPEDA Blink Analyzer MEIBOMIAN GLAND EXPRESSION Flexx MG...
by Kyle | Jul 11, 2022 | News
The biotech firm AXIM Biotechnologies Inc. AXIM reports that it has developed fast, point-of-care tests to help eye doctors detect dry eye syndrome, a big issue in today’s world. It is important to differentiate from simple allergies for proper care and treatment. Up...
by IR Team | Apr 11, 2022 | News
The challenge has been in early detection of inflammation. Matrix metalloproteinase-9 (MMP-9), an inflammatory biomarker consistently elevated in the tears of dry eye patients, may accelerate early diagnosis when detected. AXIM Biotechnologies, Inc. recently announced...
by IR Team | Apr 8, 2021 | News
Axim Biotechnologies has developed a rapid quantitative tear test to detect an inflammatory biomarker for dry eye disease, according to a press release. Diagnosis and treatment of dry eye disease (DED) can be difficult because of the discordance between signs and...
by IR Team | Mar 24, 2021 | News
AXIM Biotechnologies Inc. (AXIM.OB) said that its manufacturing partner, Empowered Diagnostics, has filed an Emergency Use Authorization or EUA application with the US Food and Drug Administration for the approval to use ImmunoPass, the company’s rapid test that...
by IR Team | Mar 17, 2021 | News
After a little over a year of expedited research, financial hardship and over 500K deaths in the US, we’re finally starting to see the light at the end of the COVID-19 tunnel. But while the widespread rollout of vaccines has been encouraging, there are many...
